Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
15 patients around the world
Available in Mexico
Dasatinib is a second-generation tyrosine kinase inhibitor that is metabolized by the
cytochrome P450. Dasatinib has shown efficacy in patients with chronic myelogenous leukemia.
Standard-dose dasatinib is 50mg-140mg/day orally, continuously. However, when combined with a
strong CYP3A4 inhibitor, a dose reduction of 75% is warranted.
This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome
inhibition with ketoconazole to reduce the dosage and costs of dasatinib for adults with
chronic myelogenous leukemia. Researchers will describe cytogenetic and molecular response
rates at 3, 6, and 12 months and adverse events (i.e., pleural effusion) associated with this
strategy.